Antibodies, Bispecific

Displaying 1 - 6 of 6CSV
Xu, J., Zhou, T., McKee, K., Zhang, B., Liu, C., Nazzari, A. F., Pegu, A., Shen, C., Becker, J. E., Bender, M. F., Chan, P., Changela, A., Chaudhary, R., Chen, X., Einav, T., Kwon, Y. D., Lin, B. C., Louder, M. K., Merriam, J. S., … Kwong, P. D. (2024). Ultrapotent Broadly Neutralizing Human‐llama Bispecific Antibodies against HIV‐1. Advanced Science, 11(26). Portico. https://doi.org/10.1002/advs.202309268
Publication Date
Bumma, N., Richter, J., Jagannath, S., Lee, H. C., Hoffman, J. E., Suvannasankha, A., Zonder, J. A., Shah, M. R., Lentzsch, S., Baz, R., Maly, J. J., Namburi, S., Pianko, M. J., Ye, J. C., Wu, K. L., Silbermann, R., Min, C.-K., Vekemans, M.-C., Munder, M., … Dhodapkar, M. V. (2024). Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma. Journal of Clinical Oncology, 42(22), 2702–2712. https://doi.org/10.1200/jco.24.01008
Publication Date
Wang, K., Du, R., Myall, N. J., Lewis, W. E., Uy, N., Hong, L., Skoulidis, F., Byers, L. A., Tsao, A., Cascone, T., Pozadzides, J., Tu, J., Negrao, M. V., Gibbons, D. L., Park, K., Rinsurongkawong, W., Lee, J. J., Gandara, D., Behl, D., … Le, X. (2024). Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC. Journal of Thoracic Oncology, 19(3), 500–506. https://doi.org/10.1016/j.jtho.2023.11.020
Publication Date
Park, K., Sabari, J. K., Haura, E. B., Shu, C. A., Spira, A., Salgia, R., Reckamp, K. L., Sanborn, R. E., Govindan, R., Bauml, J. M., Curtin, J. C., Xie, J., Roshak, A., Lorenzini, P., Millington, D., Thayu, M., Knoblauch, R. E., & Cho, B. C. (2023). Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study. Lung Cancer, 178, 166–171. https://doi.org/10.1016/j.lungcan.2023.02.008
Publication Date
Burke, A., Borot, F., Du, X., Churchill, M., Ding, J., Grass, A. M., DeSouza, P., Ali, A. M., & Mukherjee, S. (2022). A novel therapeutic bispecific format based on synthetic orthogonal heterodimers enables T cell activity against Acute myeloid leukemia. Oncogene, 42(1), 26–34. https://doi.org/10.1038/s41388-022-02532-2
Publication Date
Tavaré, R., Danton, M., Giurleo, J. T., Makonnen, S., Hickey, C., Arnold, T. C., Kelly, M. P., Fredriksson, F., Bruestle, K., Hermann, A., Ullman, E., Edelmann, K. H., Potocky, T., Dudgeon, D., Bhatt, N. B., Doubrovin, M., Barry, T., Kyratsous, C. A., Gurer, C., … Kirshner, J. R. (2022). Immuno-PET Monitoring of Lymphocytes Using the CD8-Specific Antibody REGN5054. Cancer Immunology Research, 10(10), 1190–1209. https://doi.org/10.1158/2326-6066.cir-21-0405
Publication Date